Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Zoledronic Acid Maintains BMD in Men With ADT-Treated Prostate Cancer
Key clinical point: Intravenous zoledronic acid helps maintain bone mineral density (BMD) in older men with nonmetastatic prostate cancer treated with androgen deprivation therapy (ADT).
Major finding: At 12 months, lumbar and hip BMD increased in the zoledronic acid group (2.1% and 0.8%, respectively), compared with controls (decreases of 0.9% and 4.9%, respectively; P < .05).
Study details: Prospective, single-institution, 12-month study of men aged 70 years or older receiving ADT for nonmetastatic prostate cancer.
Disclosures: The authors reported no conflicts of interest.
Citation:
Kojima et al. Osteoporos Sarcopenia. 2019 Nov 22. doi: 10.1016/j.afos.2019.11.001.